Alkem Laboratories is grabbing the Street's eyeballs

Good momentum in domestic sales and growing US business help stock movement

Alkem Laboratories, which underperformed initially after listing a year back, has gained the Street’s attention and delivered phenomenal returns of 23 per cent since February. The change in sentiment, which also makes Alkem an outlier in the pharma pack, is led by the company’s good December quarter performance. Moreover, its future prospects remain equally good.
 
The company, which derives more than 70 per cent of its revenue from domestic market, had seen concerns on new drug pricing, and later the note ban, which led to the stock’s subdued performance. But, as the note ban impact faded, sentiment improved and